Sinopharm is developing a homegrown messenger RNA inoculation for Covid-19, becoming one of the first big Chinese pharmaceutical groups to pursue the technology to combat the disease.
The state-owned pharma group’s move comes as concerns grow over the efficacy of conventional inactivated virus vaccines, which have dominated the rollout in China. Certain studies have shown the jabs produce fewer antibodies compared with mRNA shots.
Inactivated vaccines, such as Sinopharm’s existing Covid vaccine, use dead viral particles to produce an immune response, while mRNA jabs contain genetic instructions that tell cells to make viral proteins that prime the immune system.
您已閱讀20%（668字），剩余80%（2686字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。